Polymer-Protein Conjugates

<p>Introduction and General Aspects of the Technology<br>1. Evolution of Polymer Conjugation to proteins<br>2. PEGylated Proteins: A Rational Design for Mitigating Clearance Mechanisms and Altering Biodistribution<br>3. Overcoming barriers for tumor-targeted drug delivery: the power of macromolecular anticancer drugs with the EPR effect and the modulation of vascular physiology</p> <p>Toxicity and Immunogenicity Studies and Clinical Stage Conjugate Products<br>4. PEG-protein conjugates: Non-clinical and clinical toxicity considerations<br>5. Immunological responses to PEGylated proteins: anti-PEG antibodies<br>6. Immunogenicity assessment of PEGylated proteins, Lonquex, a PEGylated G-CSF case study<br>7. PEG-Protein conjugates: regulatory requirements for characterization<br>8. PEGylation of human coagulation factor VIII and other plasma proteins<br>9. Pegvorhyaluronidase Alfa: A PEGylated Recombinant Human Hyaluronidase PH20 for the Treatment of Cancers That Accumulate Hyaluronan<br>10. Challenges in the analytical characterization of PEGylated asparaginases</p> <p>Novel Site-Selective Methods of Conjugation<br>11. Glycan-targeted PEGylation for selective modification of proteins<br>12. Sialyltransferase mediated glycoPEGylation<br>13. Enzymatic approaches to new protein conjugates<br>14. Site-specific Polymer-protein conjugates by Cys mutation<br>15. Site-specific PEGylation of interferon beta-1b: from bench to clinic<br>16. Protein modification by bis-alkylation</p> <p>Alternative non-PEG polymers and architectures<br>17. In vivo properties of therapeutic bioconjugates composed of proteins and architecturally/functionally complex polymers<br>18. Poly(2-oxazoline)-protein conjugates<br>19. Polysaccharides for protein and peptide conjugation<br>20. Polysialylation of human coagulation factor VIII</p>